Last reviewed: July 7, 2026
Last updated: July 7, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Both Wegovy (semaglutide) and Mounjaro (tirzepatide) have demonstrated significant weight loss results in clinical trials, but they achieve this through distinct biological pathways. Choosing between them depends on your individual metabolism, genetic predispositions, and how your body responds to single versus dual-hormone therapy. PlexusDx helps clarify this decision through personalized medication selection and genetic insights.
How Semaglutide and Tirzepatide Differ at the Cellular Level
Semaglutide, the active ingredient in Wegovy, works by activating the GLP-1 receptor, a single hormone pathway that regulates appetite, blood sugar, and gut function. Tirzepatide, found in Mounjaro, activates both the GLP-1 receptor and the GIP receptor, creating a dual-hormone signal that amplifies the body's natural weight control mechanisms. This fundamental difference explains why many patients experience stronger appetite suppression and metabolic shifts on tirzepatide compared to semaglutide alone.
The GIP receptor, which tirzepatide uniquely targets, influences how your body stores fat and manages insulin sensitivity. When both GLP-1 and GIP pathways are activated together, the combined effect often produces more pronounced changes in how your brain perceives hunger and how your metabolism processes food. This dual-receptor approach may be particularly effective for individuals with insulin resistance or metabolic syndrome.
Weight Loss Outcomes: Clinical Trial Data and Real-World Results
In the STEP trials, semaglutide demonstrated an average weight loss of 14–17% of baseline body weight over 68 weeks when combined with lifestyle changes. In the SURPASS trials, tirzepatide showed average weight reductions of 20–22% at the highest maintenance dose over the same timeframe. While individual results vary significantly, the trial data suggests tirzepatide may produce larger average weight losses, though both medications substantially outperform diet and exercise alone.
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Side Effects and Tolerability: What Patients Actually Experience
Both semaglutide and tirzepatide commonly cause nausea, especially during the dose-escalation phase, along with constipation, decreased appetite, and occasional vomiting. Because tirzepatide's dual-pathway activation is more potent, some patients report more pronounced gastrointestinal effects or a longer adjustment period, while others tolerate it more smoothly than semaglutide. Side effects typically diminish after 4–8 weeks as the body adapts, though individual tolerance varies widely.
Rare but serious adverse events in clinical trials included pancreatitis and gallbladder complications with both agents. Either medication should be avoided in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. PlexusDx providers screen for these contraindications and discuss side-effect expectations before starting therapy to ensure informed decision-making.
Cost, Accessibility, and Why PlexusDx Offers Both Options
Brand-name Wegovy typically costs $1,300–$1,500 per month without insurance, while Mounjaro ranges similarly at $1,200–$1,400 monthly. PlexusDx compounded semaglutide injection starts at $189/mo (or $149/mo on the 6-month plan), and compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan)—both from licensed 503A compounding pharmacies. This pricing structure means patients can access either medication at a fraction of brand costs, with no membership fees or insurance requirements, and both are HSA/FSA eligible.
PlexusDx offers both semaglutide and tirzepatide because no single agent works optimally for every person. Some patients achieve excellent results on the lower-cost semaglutide option, while others benefit from tirzepatide's dual-pathway mechanism. The Precision Peptide Genetic Test helps identify which medication aligns with your genetic predispositions, eliminating costly trial-and-error and accelerating your path to sustained weight loss.
Personalization: How Genetic Testing Guides Your Best Option
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), GIPR (rs1800437), and FTO (rs9939609) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Beyond receptor genes, PlexusDx maps 14 peptide-signaling pathways and 150+ genetic insights that reveal your individual metabolic profile. A patient with genetic markers predisposing to strong GLP1R sensitivity might achieve excellent results on semaglutide, while someone with markers suggesting GIP-pathway advantage might respond better to tirzepatide. The test costs $99 as an add-on after your first month, providing clarity that informs dose selection and medication choice for months or years of therapy.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is tirzepatide always better than semaglutide for weight loss?
No. While clinical trials show tirzepatide produces larger average weight losses, individual response varies dramatically based on genetics, metabolism, and lifestyle. Some patients achieve excellent results on semaglutide alone, especially if they carry genetic variants favoring GLP-1 receptor sensitivity. PlexusDx recommends starting with the medication that aligns with your genetic profile and health goals, then adjusting if needed.
What does the Precision Peptide Genetic Test actually measure?
No — the Precision Peptide Genetic Test does not predict your response to Mounjaro or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Can I switch from semaglutide to tirzepatide if I'm not seeing results?
Yes. Many PlexusDx patients transition from one medication to another within 4–12 weeks if they plateau or tolerate one option better than the other. Switching typically requires a washout period of 1–2 weeks, after which your provider restarts with a low maintenance dose of the new medication. Your price remains flat regardless of which compound you choose—semaglutide injection starts at $189/mo (or $149/mo on the 6-month plan), tirzepatide at $289/month.
Are PlexusDx compounded medications as safe as brand-name Wegovy and Mounjaro?
PlexusDx compounds semaglutide and tirzepatide through licensed 503A compounding pharmacies, which follow strict FDA regulations and pharmaceutical standards. While compounded medications are not FDA-approved in the same way as brand products, 503A compounding pharmacies must maintain sterility, potency, and purity equivalent to manufacturer standards. All PlexusDx medications include detailed prescribing information and are prescribed by licensed physicians.
How long does it take to see weight loss on either medication?
Most patients begin noticing reduced appetite and early weight loss within 1–3 weeks of starting semaglutide or tirzepatide, with measurable weight reduction appearing by week 4–6. Significant, sustained weight loss typically emerges over 8–12 weeks as your dose stabilizes. Individual timelines vary; some patients lose weight rapidly while others progress more gradually. Consistency with medication adherence, nutrition, and physical activity accelerates results.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Take Zepbound Biweekly? Navigating Dosing Schedules for Effective Weight Loss
Navigating Mounjaro and Steroid Use: What You Need to Know for Your Weight Loss Journey